Literature DB >> 9261406

Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production.

J M Allen1, D J Debelak, T C Reynolds, A D Miller.   

Abstract

Adeno-associated virus (AAV) vector preparations are often contaminated with variable amounts of replication-competent AAV (rcAAV), which may influence the behavior of these vectors both in cultured cells and in animals. A packaging plasmid/vector plasmid system containing no significant homology and lacking the wild-type AAV p5 promoter was constructed to eliminate the production of wild-type AAV by recombination. Still, rcAAV was detected in vector produced by cotransfection of these plasmids at large scale. Sequence analysis revealed that nonhomologous recombination was responsible for the generation of these novel rcAAVs. A new AAV packaging plasmid carrying separate rep and cap expression cassettes in opposite transcriptional orientations was constructed. AAV vector preparations produced by using this packaging construct did not contain rcAAV.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9261406      PMCID: PMC191962     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  Transduction by adeno-associated virus vectors in the rabbit airway: efficiency, persistence, and readministration.

Authors:  C L Halbert; T A Standaert; M L Aitken; I E Alexander; D W Russell; A D Miller
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Defective-interfering particles of the human parvovirus adeno-associated virus.

Authors:  C A Laughlin; M W Myers; D L Risin; B J Carter
Journal:  Virology       Date:  1979-04-15       Impact factor: 3.616

3.  The genome of simian virus 40.

Authors:  V B Reddy; B Thimmappaya; R Dhar; K N Subramanian; B S Zain; J Pan; P K Ghosh; M L Celma; S M Weissman
Journal:  Science       Date:  1978-05-05       Impact factor: 47.728

4.  Structure of simian virus 40-phiX174 recombinant genomes isolated from single cells.

Authors:  E Winocour; V Lavie; I Keshet
Journal:  J Virol       Date:  1983-10       Impact factor: 5.103

5.  Nucleotide sequence and organization of the adeno-associated virus 2 genome.

Authors:  A Srivastava; E W Lusby; K I Berns
Journal:  J Virol       Date:  1983-02       Impact factor: 5.103

6.  High-efficiency ligation and recombination of DNA fragments by vertebrate cells.

Authors:  C K Miller; H M Temin
Journal:  Science       Date:  1983-05-06       Impact factor: 47.728

7.  A continuous tumor-cell line from a human lung carcinoma with properties of type II alveolar epithelial cells.

Authors:  M Lieber; B Smith; A Szakal; W Nelson-Rees; G Todaro
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

8.  Structure of mouse metallothionein-I gene and its mRNA.

Authors:  N Glanville; D M Durnam; R D Palmiter
Journal:  Nature       Date:  1981-07-16       Impact factor: 49.962

9.  Indiscriminate recombination in simian virus 40-infected monkey cells.

Authors:  E Winocour; I Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

10.  Quantitation of a simian virus 40 nonhomologous recombination pathway.

Authors:  D L Dorsett; I Keshet; E Winocour
Journal:  J Virol       Date:  1983-10       Impact factor: 5.103

View more
  26 in total

Review 1.  Adeno-associated virus vectors and hematology.

Authors:  D W Russell; M A Kay
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

2.  High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids.

Authors:  L Cao; Y Liu; M J During; W Xiao
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Comparative analysis reveals frequent recombination in the parvoviruses.

Authors:  Laura A Shackelton; Karin Hoelzer; Colin R Parrish; Edward C Holmes
Journal:  J Gen Virol       Date:  2007-12       Impact factor: 3.891

4.  Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses.

Authors:  Bernd Hauck; Samuel L Murphy; Peter H Smith; Guang Qu; Xingge Liu; Olga Zelenaia; Federico Mingozzi; Jürg M Sommer; Katherine A High; J Fraser Wright
Journal:  Mol Ther       Date:  2008-10-21       Impact factor: 11.454

5.  Improved splicing of adeno-associated viral (AAV) capsid protein-supplying pre-mRNAs leads to increased recombinant AAV vector production.

Authors:  K David Farris; David J Pintel
Journal:  Hum Gene Ther       Date:  2008-12       Impact factor: 5.695

6.  Characterization of wild-type adeno-associated virus type 2-like particles generated during recombinant viral vector production and strategies for their elimination.

Authors:  X S Wang; B Khuntirat; K Qing; S Ponnazhagan; D M Kube; S Zhou; V J Dwarki; A Srivastava
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

7.  Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial.

Authors:  James A Allay; Susan Sleep; Scott Long; David M Tillman; Rob Clark; Gael Carney; Paolo Fagone; Jenny H McIntosh; Arthur W Nienhuis; Andrew M Davidoff; Amit C Nathwani; John T Gray
Journal:  Hum Gene Ther       Date:  2011-05       Impact factor: 5.695

8.  Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles.

Authors:  Pascale Nony; Gilliane Chadeuf; Jacques Tessier; Philippe Moullier; Anna Salvetti
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  A high-throughput hybridization method for titer determination of viruses and gene therapy vectors.

Authors:  E M Atkinson; D J Debelak; L A Hart; T C Reynolds
Journal:  Nucleic Acids Res       Date:  1998-06-01       Impact factor: 16.971

10.  Within-host genetic diversity of endemic and emerging parvoviruses of dogs and cats.

Authors:  Karin Hoelzer; Laura A Shackelton; Edward C Holmes; Colin R Parrish
Journal:  J Virol       Date:  2008-09-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.